EQS-News: GeoVax to Review 2024 Progress at Biotech Showcase During J.P. Morgan Healthcare Week 2025

ATLANTA, GA - January 6, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, Chief Executive Officer, will review 2024 progress in a presentation at the Biotech Showcase coinciding with the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, January 13-16, 2025.

A live webcast of the presentation will be available here.  A replay will be available approximately 2 hours after the presentation and accessible for three months. Additionally, senior management of GeoVax will be available for one-on-one meetings during the week with potential partners, collaborators, and investors. One-on-one appointments may be requested as follows:

• Through the Biotech Showcase partnering platform here.  
• Through the Biotechnology Innovation Organization (BIO) partnering platform here.
• Direct outreach to the Company at info@geovax.com or to Precision AQ at maxmilian.gadicke@precisionaq.com

 About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines for many of the world’s most threatening infectious diseases and therapies for solid tumor cancers. The company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine for which GeoVax was recently awarded a BARDA-funded contract to sponsor a 10,000-participant Phase 2b clinical trial to evaluate the efficacy of GEO-CM04S1 versus an approved COVID-19 vaccine. In addition, GEO-CM04S1 is currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. A Phase 2 clinical trial in first recurrent head and neck cancer, evaluating Gedeptin® combined with an immune checkpoint inhibitor is planned to initiate during the first half of 2025. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. The Company has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

View the original release on www.newmediawire.com